Breaking WORLD PHARMA NEWS🔒 SSL Verified
Live Data Status: |News & Media
Welcome to the detailed analysis for worldpharmanews.com. This domain is officially recognized as Breaking World Pharma News. According to their official web presence, their primary focus is: "World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharm".
Table of Contents
- ↓ AI designs a novel E. coli killer
- ↓ GLP-1 drug linked to heart benefits for high-risk patients
- ↓ FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- ↓ Targeting MDA-9 restrains head and neck tumor growth and eliminates therapy resistance
- ↓ Engineered human neurons rebuild damaged spinal cord circuits
- ↓ Top Alternatives to worldpharmanews.com
- Tech Stack
- Custom Built / Unknown
- Link Profile
- Internal Pages: 88Outbound Links: 6
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$4,500
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- worldpharmanews.comTaken
- worldpharmanews.netTaken
- worldpharmanews.orgTaken
- worldpharmanews.ioTaken
- worldpharmanews.coAvailable
- worldpharmanews.aiAvailable
Official Contact & Profiles
Content Snippets from worldpharmanews.com
"Your online source for breaking international pharma news coverage"
"And so it is that chemical engineer Brian Hie and bioengineering graduate student Samuel King came to study bacteriophage ΦX174 (pronounced “FYE-ex-1-7-4”)."
"Randomised trials and observational studies have shown non-inferior effects of tirzepatide compared to another GLP-1 receptor agonist, dulaglutide, for major adverse cardiovascular events (MACE) - a combined measure of heart attack, stroke, and death from any cause."
"Despite advances in emergency care and rehabilitation, no approved therapies exist to rebuild the neurons and connections lost after a spinal cord injury."
Key Topics & Focus Areas for worldpharmanews.com:
AI designs a novel E. coli killer
GLP-1 drug linked to heart benefits for high-risk patients
FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
Targeting MDA-9 restrains head and neck tumor growth and eliminates therapy resistance
Engineered human neurons rebuild damaged spinal cord circuits
By comparing worldpharmanews.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to worldpharmanews.com.
Frequently Asked Questions
Is worldpharmanews.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of worldpharmanews.com?
As of September 27, 2026, worldpharmanews.com holds an estimated domain authority score of 75/100 based on our VisitRank tracking algorithms.
What are the top alternatives to worldpharmanews.com?
You can find the best alternatives and similar sites to worldpharmanews.com in our explore section, which includes competitors in the News & Media sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for worldpharmanews.com:
wroldpharmanews.comwoldpharmanews.comwoorldpharmanews.comworldpharmanews.comworldphermanews.comworldpharmenews.comworldpharmanaws.comwirldpharmanews.comwkrldpharmanews.com